Needham & Company Upgrades Boston Scientific (BSX) to Buy

Needham & Company upgraded Boston Scientific (NYSE: BSX) from Hold to Buy with a price target of $21.00.

Analyst Mike Matson commented, "We are upgrading BSX to Buy given 1) a strong product cycle that we expect to drive revenue growth acceleration during 2016, 2) our expectation that BSX can continue to see significant (above-peer) margin expansion, 3) our belief that consensus estimates are conservative, and 4) our view that BSX shares are undervalued."

For an analyst ratings summary and ratings history on Boston Scientific click here. For more ratings news on Boston Scientific click here.

Shares of Boston Scientific closed at $16.31 yesterday.

You May Also Be Interested In

• Stifel Upgrades Barry Callebaut AG (BARN:SW) (BYCBF) to Buy
• UBS Upgrades Rivian Automotive Inc (RIVN) to Neutral, 'More balanced at current levels'
• Oppenheimer Upgrades Avalo Therapeutics (AVTX) to Outperform following AVTX-009 acquisition